This is a double-blinded, placebo-controlled, crossover trial of THC and CBD in equal amounts in adults with severe Tourette syndrome. Tourette syndrome is a neurological disorder that develops in childhood and is characterised by involuntary movements and vocalizations (known as tics), which may be painful, embarrassing and functionally impairing. Each participant will complete two periods of treatment with either THC:CBD or placebo, with a break in between each period. The objective of this trial is to examine the safety and efficacy of CBD:THC on tic frequency as well as the psychiatric and cognitive symptoms associated with Tourette syndrome, relative to placebo.
The Lambert Initiative in collaboration with Bod Australia Limited will be supplying the pharmaceutical grade cannabis extract to be used in the trial.
This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, and Wesley Medical Research.
Chief Investigator: Dr Philip Mosley (Wesley Medical Research)
Project Coordinator: Tracy Grierson (Wesley Medical Research)
For more information, please contact: firstname.lastname@example.org